Non-invasive fetal genetic screening by digtal analysis
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsSTEPHEN QUAKE, HEI-MUN CHRISTINA FAN
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsSTEPHEN QUAKE, HEI-MUN CHRISTINA FAN
Estimating the term…
The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital analysis is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents.
A method for identifying a risk for an aneuploidy on a first chromosome of a fetus carried by mother, the method comprising:
A method for identifying a risk for an aneuploidy on a first chromosome of a fetus carried by a mother, the method comprising:
A method for identifying a risk for an aneuploidy on a first chromosome of a fetus carried by mother, the method comprising:
A method for identifying a risk for an aneuploidy on a first chromosome of a fetus carried by a mother, the method comprising:
Dependencies are inferred from the claim text.